Capital World Investors Gilead Sciences, Inc. Transaction History
Capital World Investors
- $659 Billion
- Q2 2025
A detailed history of Capital World Investors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital World Investors holds 46,303,299 shares of GILD stock, worth $5.21 Billion. This represents 0.78% of its overall portfolio holdings.
Number of Shares
46,303,299
Previous 53,547,901
13.53%
Holding current value
$5.21 Billion
Previous $6 Billion
14.44%
% of portfolio
0.78%
Previous 1.01%
Shares
32 transactions
Others Institutions Holding GILD
# of Institutions
2,327Shares Held
1.02BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$13.6 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$13.4 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$6.66 Billion0.25% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.22 Billion0.79% of portfolio
-
Capital Research Global Investors Los Angeles, CA31.1MShares$3.5 Billion0.72% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $141B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...